key: cord-0946762-gii6qoe6
authors: Casado, Jose L; Vizcarra, Pilar; Velasco, Hector; Hammerle, Johannes; McGee, Amaranta; Fernandez-Escribano, Marina; Vallejo, Alejandro
title: Progressive and parallel decline of humoral and T cell immunity in convalescent health care workers with asymptomatic or mild-moderate SARS-CoV-2 infection
date: 2021-05-07
journal: J Infect Dis
DOI: 10.1093/infdis/jiab242
sha: fdd3ec15018cf3c2631e1c2b3641b59fc39107dd
doc_id: 946762
cord_uid: gii6qoe6

We investigated the duration of humoral and T-cell immune response in paired samples among 22 convalescent health care workers (HCWs). A median of 1.8 months after diagnosis, T-cell response was significantly lower in HCWs with early loss of antibodies (6 cases, 27%). After 5.1 months, antibodies decline was observed in 77% of cases (41% seroreverted; p<0.01), and 36% have lost T-cell response (75% lost response to spike protein). Persistence of immune response was observed in those who developed a greater adaptative immune response. Our data point to the initial immune response as the relevant player in COVID-19 duration of protection.

M a n u s c r i p t 3

It is estimated that 40-75% of COVID-19 infections could be mild or asymptomatic [1] , and previous studies have demonstrated that humoral immune response wane quickly after infection [2] . Nevertheless, it has been shown that convalescent patients harbored polyfunctional SARS-CoV-2-specific T cells that display a stem like memory phenotype [3] although in a recent study, SARS-CoV-2-specific CD4+ and CD8+ T-cells declined with a half-life of 3-5 months [4] .

Of importance, the susceptibility to re-infection could be hypothetically higher in the fraction of the SARS-CoV-2-infected population with particularly low immune memory, especially in the case of close and continued contact with the virus such as frontline health care workers (HCWs). Thus, we focused this study on a cohort of convalescent HCWs who were prospectively assessed after the infection to ascertain the persistence of humoral and CD4+ and CD8+ T-cell response against SARS CoV-2.

This study was the continuation of a cross-sectional study performed in May 2020 at a tertiary university hospital. At that time, convalescent HCWs underwent blood analysis to evaluate the presence of humoral and reactive T-cell immune response. Then, they were reevaluated after 6 months to ascertain the evolution of humoral and cellular response. Mild disease was defined as the presence of symptoms attributable to COVID-19 in absence of radiological infiltrates and lack of hypoxemia (oxygen saturation ≥95% on room air).

Moderate disease was defined in case of radiological infiltrates with oxygen saturation ≥95% on room air. The initial cross-sectional study was approved by our ethic committee (EC162/20) and registered at clinicaltrials.gov (NCT04402827). Written informed consent was obtained from all the participants. 

The COVEX study included 22 HCWs (median age, 34 years; 10 females and 22 males). Supplementary Table 1 Figure 1A) . Thus, seroreversion was observed for those with the initial lowest ELISA titers of antibodies (24.8 vs 11.1; p=0.001).

We were able to repeat the evaluation of T-cell response in 16 HCWs. Five (31%) were not reactive, and there was a variation in the breadth and magnitude of SARS-CoV-2-specific responses (Figure 1B-1C) . Of note, 9 out of 12 HCWs have lost T cell response to protein S. There was a significant association between humoral and T-cell response: loss of any Tcell response was observed in young HCWs who had a less severe disease (84% asymptomatic), with lower level of antibodies at inclusion (p=0.005) and at the end of follow up (p=0.019).

To test the impact of the initial immunological response, we evaluated 10 pro-and antiinflammatory cytokines at inclusion. An increased production of IFN-γ, IL-2, and IL-6 against protein S, and up-regulation of IFN-γ, TNF-α, GM-CSF, IL-17, IL-2 and IL-6 and of IL-10 against protein M were significantly associated with persistent humoral response (Figure 2) .

Thus, an increased Th1 response against viral peptides was associated with persistence of specific antibodies against SARS-CoV-2 (p=0.017).

During an median additional follow up of 116 days (IQR, 96-131), 5 HCWs were studied because of suggestive symptoms (sore throat, headache) or close contact with COVID-19 A c c e p t e d M a n u s c r i p t 7 patients/partner, without any demonstrated case of reinfection, despite the fact that most of them continued working on the frontline of COVID-19.

The durability of infection-induced SARS-CoV-2 immunity has major implications for Although SARS-CoV-2 elicit a robust B cell response, cumulative evidence showed a loss of specific humoral response to SARS-CoV-2 after disease, that ranged from 14 to 50% of initially positive patients [2, 5] . In our study, we found that 27% of convalescent HCWs have lost specific antibodies as early as 2 months, a rate that increased to 41% in a short follow up. In line with this, a recent study referred a constant decline in the level of antibodies in up to 94% of HCWs [6] .

Nevertheless, it was unclear whether this decrease in SARS-CoV-2 antibodies represent the normal evolution following pathogen clearance [7] , with maintenance of protective T-cell mediated responses. Nevertheless, we observed a relation between initial humoral and T cell response, and a weak cellular response was observed in those with early loss of antibodies, as previously reported [3] . Moreover, we also observed a decline in the rate of Tcell response during follow up, highlighting the loss of response to protein S in 75% of cases.

Previous studies demonstrate that the factors involved with a shorter duration of humoral response were a younger age, lower severity of disease, or a lower initial viral load [2, 8] . It has been hypothesized that the failure of the early/innate immune control makes necessary a larger adaptive response as seen in more severe cases of influenza [9] : a mild-moderate disease could produce a greater systemic response than that observed in asymptomatic cases, and such individuals appear to mount a more vigorous T-cell response. In line with A c c e p t e d M a n u s c r i p t 8 this, a recent study found that the lack of response in asymptomatic patients is due to a higher frequency of NK cells and early and transient increase of specific IgA, highlighting the role of the innate response [10] .

We confirmed the importance of the adaptative immune response. It has been shown that asymptomatic individuals had a reduced inflammatory response characterized by low circulating concentrations of cytokines and chemokines [2] . Our analysis of cytokines release after cell stimulation revealed up-regulation of pro-and anti-inflammatory cytokines in mildmoderate disease in comparison with asymptomatic, with an adequate Th1 in those maintaining both humoral and T cell response [11] . Indeed, current evidences strongly indicated that Th1 type response is a key for successful control of SARS-CoV-2.

Furthermore, we observed an initial response significantly greater to peptide M, a peptide with 90% of structural homology between different coronavirus [12] , suggesting the possible protective role of a background of cross-reactive immunity as observed in unexposed individuals [13, 14] .

We did not observe any case of reinfection in our small cohort. As hypothesis, the failure to detect T cell response does not rule out the capacity of eliciting an immune response, which could be sufficient to control viral replication efficiently.

Nevertheless, we consider that we do not have enough sample size and systematic follow up to be able to correctly assess this question.

Our study has several limitations, including the small sample of convalescent HCWs. A false positive serologic result in those with negative RT-PCR was possible but unlikely, because of the high sensitivity of repeated serological test. Indeed, a similar initial T-cell response in breadth and magnitude was observed in these participants, in comparison with RT-PCR positive individuals. Also, we quantified cytokines in PBMCs after stimulation, therefore produced by different immune cells, trying to mimic the overall response in vivo, an approach recently evaluated in SARS-CoV-2 infected patients [15] . Finally, we determine T cell A c c e p t e d M a n u s c r i p t 9 response to 3 structural viral proteins, and not include other viral immunodominant epitopes as ORF1, limiting our vision of the breadth of cellular immune response.

In conclusion, we found a close and parallel relation between humoral and cellular immune response to SARS CoV-2 in convalescent HCWs with asymptomatic or mild disease.

Whereas age and severity are clinical factors, the development of a well-balanced adaptative immune response is responsible for the magnitude and duration of response. In any case, more research is needed to clarify the mechanisms underlying immune responses across the spectrum of clinical presentations and to evaluate the durability of immunity elicited by primary SARS-CoV-2 infection or vaccination.

A c c e p t e d M a n u s c r i p t 

Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Immunological memory to SARS-CoV-2 assessed for up to eight months after infection

Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network -12 States

Among Frontline Health Care Personnel in a Multistate Hospital Network -13

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity

High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection

Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

Understanding SARS-CoV-2: Genetic Diversity, Transmission and Cure in Human

A structural analysis of M protein in coronavirus assembly and morphology

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients

We would like to express our deepest thanks to the HCWs for their participation into the study. We also thank Ana Abad for her assistance in database management.

The study was funded, in part, by a grant from Instituto de Salud Carlos III (ISCIII COV-20-01304).

Jose L Casado and Alejandro Vallejo contributed equally to this work. JC and AV conceived of and designed the study, analyzed the results, and wrote the manuscript; HV conducted the study and performed analytical determinations; PV, JH, AMcG, MFE conducted the study and collected data, revised the manuscript, and approved the final version.

Requests for materials or data should be addressed to corresponding authors upon request.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t